The current European legislation for in vitro diagnostic medical devices (IVD) (Regulation 2017/746 or the IVDR) has created challenges not only for IVD manufacturers but also for pharmaceutical ...
DUBLIN--(BUSINESS WIRE)--The "Physician Office In Vitro Diagnostic (IVD) Test Markets" report has been added to ResearchAndMarkets.com's offering. This report analyzes trends in global demand for in ...
Until now, confirming ApoE4 carrier status in Alzheimer's patients has relied on molecular DNA testing. The Elecsys ApoE4 test offers a simple, fast and reliable option, using a minimally-invasive ...
Company also has a lung cancer test in development. Epigenomics confirmed the European launch of Epi proColon, reportedly the first CE-marked IVD blood test for detecting colorectal cancer. The ...
Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable ...
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results